Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a
- PDF / 498,370 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 237 Views
REVIEW ARTICLE
Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis Maryam Zaman 1 & Roha Saeed Memon 1 & Arooba Amjad 1 & Tehlil Rizwan 1 & Jai Kumar 1 & Ibtehaj ul Haque 1 & Syed Saad Ali 1 & Lin Li 2 & Muhammad Shariq Usman 1 Received: 1 May 2020 / Accepted: 24 August 2020 # Springer Nature Switzerland AG 2020
Abstract Purpose To conduct a meta-analysis to evaluate the effect of ertugliflozin on long-term hemoglobin A1c (HbA1c), body weight and blood pressure (BP). Methods Online databases available were searched from their inception to February 2020. Randomized controlled trials (RCTs) comparing ertugliflozin to either placebo or an active control drug were included. Data on four efficacy outcomes were extracted, namely: HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP) and body weight. Continuous outcomes were pooled using a random-effects model and presented as weighted mean differences (WMDs) and corresponding 95% CIs. Additionally, a subgroup analysis was done to compare two doses of ertugliflozin (5 mg and 15 mg). A sensitivity analysis was also performed by eliminating studies using active drugs as controls. Results From a total of 123 search results, eight studies were included. Compared to the control group, ertugliflozin was associated with a significant decrease in SBP (WMD: −3.64 mmHg, 95% CI [−4.39,-2.90]; p < 0.001; I2 = 0%) and DBP (WMD: −1.13 mmHg, 95% CI [−1.67,-0.60], p < 0.001; I2 = 0%). Similarly, significant reductions in body weight (WMD: −2.35 kg, 95% CI [−2.94,-1.77]; p < 0.001; I2 = 0%) as well as HbA1c (WMD: −0.41%, 95% CI [−0.62,-0.20]; p < 0.001; I2 = 0%) were seen with ertugliflozin. Subgroup analysis demonstrated no significant difference in efficacy between the two doses in any of the four outcomes. Conclusion Ertugliflozin results in significant reductions in HbA1c, body weight, SBP and DBP, when compared to control. Subgroup analyses suggest that these effects are not dose-dependent. Keywords Sodium-glucose co-transporter 2 inhibitor . Biomarkers . HbA1c . Steglatro
Introduction Type-2 diabetes (T2D) has a well-known association with obesity and cardiovascular diseases (CVDs). Obesity-related
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40200-020-00623-z) contains supplementary material, which is available to authorized users. * Maryam Zaman [email protected] 1
Internal Medicine, Ruth KM Pfau Civil Hospital, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi 74000, Pakistan
2
Department of Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, USA
insulin resistance leads to the development of T2D which, together with obesity, serves as a major risk factor for developing CVDs [1]. Furthermore, CVDs contribute to two-thirds of all the T2D-related deaths [2, 3]. Even though T2D and CVDs are closely linked, most traditional anti-glycemic agents do not reduce cardiovascular event
Data Loading...
